What Prostate Cancer Research does

Prostate Cancer Research (PCR) is a UK-registered charity (No: 1156027) founded in 1989 and headquartered in London, focused on funding research to improve survival and find cures for men with advanced prostate cancer. The charity operates three distinct sub-brands. The Infopool is a co-designed, annually-reviewed patient information platform covering testing, diagnosis, treatment choices, side effects, and a clinical trial finder. Prostate Progress is a national patient data registry, launched in 2026, that links patient-reported experience to NHS records to accelerate research and reduce health inequalities. Proven Connect is PCR's translational research arm, structured to identify promising diagnostics and treatments, build a portfolio of early-stage companies, and partner with investors to accelerate clinical translation.

PCR generates revenue through diversified donation streams: individual giving, challenge-event fundraising (London Marathon, Brighton Marathon, treks, cycle rides), corporate partnerships, payroll giving, legacy giving via a partnership with Octopus Legacy, retail donations via easyfundraising's network of 7,000 brands, and trust/foundation grants. Pharmaceutical partnerships, such as the collaboration with Ipsen Ltd on the Real Talk campaign and the joint grant round with Breast Cancer Now, supplement research funding. PCR also pursues policy influence, including the establishment of the All-Party Parliamentary Group on Prostate Cancer in January 2025 and a coalition of 18 organisations advocating for national screening reform, with research awards to date exceeding £7.5 million during the 2018-2024 chair tenure of Matt Ellis.

The organisation serves four primary stakeholder groups: men affected by prostate cancer and their families (with a specific focus on Black men, who face a 1-in-4 lifetime risk versus 1-in-8 for White men); academic researchers and clinicians at institutions including Cambridge, Imperial, Newcastle, Harvard, and Dana-Farber; general public donors and fundraisers; and policymakers and NHS decision-makers. PCR operates a community-led go-to-market approach across digital platforms (website, the Infopool, Prostate Progress), earned media campaigns (Proactive for Your Prostate, Real Talk), and event-based fundraising, with advocacy amplified through high-profile supporters and a multi-tiered management structure under CEO Oliver Kemp MBE.

Name

Prostate Cancer Research

Legal name

Prostate Cancer Research

Website

https://prostate-cancer-research.org.uk

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

Prostate Cancer Research is a UK charity funding research, patient data platforms (Prostate Progress), patient information (the Infopool), and translational venture-building (Proven Connect) for men affected by prostate cancer.

Ownership category

akta.pro rank

Product category

Prostate cancer research charity

NAICS

Voluntary Health Organizations (813212), Scientific Research and Development Services (5417)

SIC

Services-Social Services (8300)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Research & Science Grantmaking Foundations (BPAGAKAI), Research Administration & Grants Management Support (Pre/Post-Award, Compliance) (EDAEALAO)

Keywords

• Cancer research funding
• Patient information platform
• Translational research investment
• Health advocacy campaigns
• Charitable fundraising events

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Marketing or Sales, Technology or R&D, Operations, Others

Revenue model

1. Donations and Fundraising: PCR raises funds through individual donations, event-based fundraising (marathons, treks, challenge events), corporate partnerships, and payroll giving schemes. The organization also generates donations through easyfundraising partnerships with 7,000 online retail brands.
2. Legacy Giving: PCR receives gifts left in supporters' Wills, with legacy pledging facilitated through a partnership with Octopus Legacy that offers free or discounted will-writing services.
3. Trust and Foundation Grants: PCR receives grants from trusts and foundations to fund research and patient engagement activities, including its Racial Disparities Grant Programme and Bone Metastasis Collaboration Fund with Breast Cancer Now.
4. Pharmaceutical and Corporate Partnerships: PCR partners with pharmaceutical companies on patient involvement projects and collaborates with corporations for innovative charity partnerships that raise awareness and engage employees in fundraising.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

Prostate Cancer Research is a UK-registered charity that funds prostate cancer research, delivers patient-facing information platforms (The Infopool), operates a national patient data registry (Prostate Progress), and runs a translational research investment arm (Proven Connect). It mobilises donor income through fundraising events, corporate partnerships, trust grants and legacy giving, and advocates for national screening reform and health equity for Black men.

Product overview

Prostate Cancer Research operates as a charitable organization rather than a traditional product company. Their core offerings consist of patient-facing platforms (The Infopool and Prostate Progress), a translational research initiative (Proven Connect), and advocacy campaigns (Proactive For Your Prostate and Real Talk). The Infopool provides patient education, Prostate Progress collects patient data for research, and Proven Connect translates research into clinical applications.

Differentiator

Problem solved

Functional benefit

Brands

• the infopool: Patient information platform providing easy to understand information on testing and diagnosis, treatment choices, living with side effects and clinical trial finder. Created by Prostate Cancer Research and co-designed with patients and clinicians.
• Proven Connect
• Prostate Progress

Products and services

• The Infopool A co-designed, plain-English patient information platform providing accessible resources on testing, diagnosis, treatment choices, living with side effects, and a clinical trial finder. Written based on latest evidence, reviewed annually, and aligned with clinical guidelines for men affected by prostate cancer and their families.
• Prostate Progress A national patient data registry that collects patient experience data and links it to NHS records to accelerate prostate cancer research, personalise care, reduce health inequalities and improve outcomes. Patients complete online surveys and consent to linkage with NHS records for research purposes.
• Proven Connect The translational research arm of PCR that drives transformation of research into real-world treatments and diagnostics, building a portfolio of early-stage companies and partnering with investors to accelerate new innovations for prostate cancer patients.

Quantifiable outcome

• 13% reduction in prostate cancer deaths with PSA screening in European trial of 162,000 men
• +5 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Ipsen LtdcoreGTM or Marketing Partner · 20 September 2024PCR collaborated with pharmaceutical company Ipsen on the Real Talk campaign addressing racial disparities in Black men's prostate cancer awareness. The amplification of the campaign was partially funded by Ipsen Ltd. PCR and Ipsen also co-hosted the 'What to Expect: A Guide to Prostate Cancer' webinar series.
• Breast Cancer NowcoreStrategic or Co-development Partner · 5 September 2024PCR partnered with Breast Cancer Now to launch the Bone Metastasis Collaboration Fund, a joint £600,000 funding initiative to tackle the spread of both breast and prostate cancers to the bones. The initiative focuses on uncovering why tumours spread to the bone and exploring underlying mechanisms of bone metastases.
• Octopus LegacyminorGTM or Marketing PartnerPCR partnered with Octopus Legacy, expert estate planners, to offer supporters free or discounted will-writing services. The cost of a will is covered by PCR up to £150, enabling supporters to include a legacy gift to the charity.
• easyfundraisingminorChannel Partner/ Reseller/ DistributorPCR receives donations through easyfundraising's network of over 7,000 online retail brands (including eBay, Argos, John Lewis, ASOS, Booking.com, and M&S) when supporters shop through the platform.
• Tackle Prostate CancercoreStrategic or Co-development PartnerPCR collaborated with Tackle Prostate Cancer to run the 'Living Well with Prostate Cancer' webinar series in 2021, providing information and support to people affected by prostate cancer.
• Worldwide Cancer ResearchcoreStrategic or Co-development PartnerPCR and Worldwide Cancer Research co-sponsored an award for research at Imperial College London on targeting prostate cancer's Achilles' heel (DNA damage). They also announced a joint Grant Round opening 23 February 2026 seeking innovative ideas to help end cancer.
• Prostate Cancer UKcoreStrategic or Co-development PartnerPCR and Prostate Cancer UK issued a joint statement on the National Screening Committee's review of prostate cancer screening, forming part of a coalition of 18 leading organizations advocating for reform.
• The Rose Thompson FoundationminorStrategic or Co-development PartnerPartnered with PCR to introduce the Infopool to African-Caribbean communities across the Midlands, supporting culturally-tailored engagement strategies for Black communities.
• Proven ConnectcoreStrategic or Co-development PartnerProven Connect is the translational research arm of PCR, helping early-stage companies transform promising lab discoveries into real-world diagnostics and treatments. It is an integral part of PCR's ecosystem, building a portfolio of early-stage companies and partnering with investors.
• Information Security ForumminorStrategic or Co-development PartnerPCR and the Information Security Forum are working together towards a world where no man is left behind, collaborating on initiatives related to prostate cancer awareness and data security.
• UK Research and Innovation (UKRI)coreStrategic or Co-development PartnerPCR announced a UKRI Investment Partnership to advance prostate cancer research, combining public and charitable funding to accelerate research programmes.
• Association of Medical Research Charities (AMRC)coreOthersPCR is a member charity of AMRC and operates according to AMRC's Principles of peer review, ensuring best-practice standards in research funding decisions.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• The Institute of Cancer Research: UK research institution and charity that conducts cancer research including prostate cancer. PCR funds research at partner institutions and ICR represents a comparable research-grantmaking and translational-research model.

Broad incumbents

• Cancer Research UK: The UK's largest cancer charity, funding broad cancer research including prostate cancer. Overlaps with PCR in research funding and public health advocacy, but operates at much greater scale and across all cancer types.
• Macmillan Cancer Support: UK's largest cancer support charity, providing patient information and support services. Overlaps with PCR's Infopool and patient-facing support work, but operates across all cancer types at much greater scale.
• British Heart Foundation: One of the UK's largest health research charities. Comparable as a major UK health research grantmaker and charity running research funding, patient information, and large-scale fundraising operations.

Direct peers

• Movember Foundation: Global men's health charity that funds prostate cancer research and runs the largest male-focused fundraising campaign. Competes globally for donor mindshare in men's health and prostate cancer research funding.
• Prostate Cancer UK: The largest UK prostate cancer charity. PCR explicitly partners with it on screening advocacy and competes for the same donor pool, grants, and policy influence in prostate cancer research and patient support.
• Breast Cancer Now: UK breast cancer research and support charity that has partnered with PCR on the Bone Metastasis Collaboration Fund. Operates a comparable model of research funding, patient information, and advocacy in a sister disease area.
• Worldwide Cancer Research: UK-based cancer research charity funding innovative research globally. PCR and Worldwide Cancer Research co-sponsor research grants and joint grant rounds, making them direct peers in the research-funding space.
• Tackle Prostate Cancer: UK prostate cancer support and advocacy organisation. PCR has partnered with it on the 'Living Well with Prostate Cancer' webinar series, and they compete/collaborate for prostate cancer patient engagement and community outreach.

Regional players

• Pancreatic Cancer UK: UK disease-specific cancer charity operating a similar model of research funding, patient support, and advocacy in a different cancer. Comparable peer structure to PCR as a mid-sized UK cancer charity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/PCR_News
• Facebookfacebook.com/Prostatecancerresearchnews
• Instagraminstagram.com/prostatecancerresearch

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prostate Cancer Research